| As Korea’s only developer of an AAV-based gene therapy for wAMD, Elisigen is advancing clinical development while leveraging its successful Series C financing to pursue global licensing and a KOSDAQ IPO. |
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.